Grey Market Premium (GMP) in IPO: Meaning and Limits

The absence of regularity oversights in the grey market premium of IPOs raises concerns about price manipulation.

Participants may spread false information or mislead potential investors to influence grey market premiums.

Insider trading leads to unfair advantages and potential fraud.

No shares change hands on deal day. A grey market trade is a private promise: the seller agrees to deliver shares, or the benefit of an application, once allotment or listing happens, at a price agreed today. Settlement runs in two stages — deals tied to allotment square off when the basis of allotment is out, and pure GMP deals square off around listing day. The whole system runs on dealer networks and reputation. No exchange, no margin collection, no record anyone can audit, and the money at risk is the deal amount itself.

Dealers do one piece of arithmetic with the number: expected listing price = issue price + GMP. Using the example above, a Rs 200 issue quoting Rs 230 implies the market expects a Rs 30 pop on debut. That is a useful read on demand and a useless read on the business — and because a handful of dealers effectively set the quote for everyone else, the same figure gets repeated across every GMP website within the hour.

A Kostak deal sells your entire IPO application before allotment is declared, at a fixed rate. The buyer pays whether your application wins shares or not — that certainty is exactly why Kostak rates sit below the alternatives. You take a sure, smaller amount and hand over whatever the application might have become.

A subject-to-sauda deal pays only if your application is actually allotted. Since the seller carries the allotment risk, subject-to rates run higher than Kostak rates on the same issue. If allotment comes through, the buyer takes the benefit at the agreed rate; if it does not, the deal lapses with nothing owed on either side.

Dealers quote all three together on hot issues. Sellers who want out early usually trade Kostak or subject-to-sauda; GMP gets the headlines because it doubles as a listing forecast.

Three kinds of participants, with three different agendas. Buyers are betting the stock lists above the deal price. Sellers — usually applicants with no intention of holding — are locking in a sure profit and giving up the chance of a bigger one. Dealers sit between them, matching sides and publishing the rates, and they carry the default risk of everyone they broker for. That last point matters: the dealer quoting you a rate is extending informal credit to a stranger, which is why established networks dominate and newcomers get burned.

The GMP trackers you see online aggregate dealer quotes submitted by phone or chat — there is no exchange feed behind them. Some are honest aggregations of a thin market; a few are promotional, especially around issues their operators want crowded. Cross-checking two or three trackers for the same issue is the minimum hygiene. When they disagree, the disagreement itself is the information: the market has no single price because there is no market, only conversations.

• Quotes are thin and private, so a handful of orders can double or halve a rate in an afternoon.
• There is no published record; websites that collate GMP rely on voluntary dealer reports with nothing to verify them against.
• Bad news travels the same channels as hype — a weak day-2 subscription or a market wobble collapses premiums as fast as they were built.
• For small issues, a few operators can push the quote up deliberately to pull retail applications into the book.

Grey market quotes arrive in the same inbox as subscription multiples and listing-day percentages, and they answer different questions:

A crowded book tells you allotment will be scarce. A fat GMP tells you traders are optimistic. Neither tells you the business is worth the price being asked — that question is answered by the RHP and peer valuation, which is where the decision actually lives.

Exit routes are taxed differently, and the difference surprises people at filing time. Sell an application before allotment — a Kostak or subject-to-sauda deal — and the receipt is generally treated as business income at your slab rate. Get the allotment and sell after listing instead, and normal capital gains rules apply: 20% short-term within a year of allotment, 12.5% long-term beyond that. The full working sits in our tax on IPO allotment guide.

GMP is useful for exactly one input: gauging how crowded an issue is before you commit. It says nothing about the valuation, the promoters, or what the stock does in year three. Any plan that depends on the stock listing above a certain price — applying purely for the pop, borrowing to bid, promising someone a share of listing gains — is already fragile, and the grey market is the wrong place to look for reassurance. The boring alternative stands: read the RHP, compare with listed peers, size the application like a normal stock purchase, and let the allotment lottery do what it does.

Grey market premiums come with risk and are not guaranteed indicators of future stock performance.

Actual performance after stock listing may differ from grey market expectations.

Investors should do thorough research and consider various factors before investing.